A Short FDA Delay. For What?

A drug has not-so-great side effects, but treats a debilitating disease like epilepsy. In the gray area of risk-benefit analysis, the Food and Drug Administration is likely to take the advice of its outside experts. So when a panel unanimously backed the effectiveness and said the side effects of GlaxoSmithKline (NYSE: GSK  ) and Valeant Pharmaceuticals' (NYSE: VRX  ) ezogabine could be managed, the drug seemed like a shoo-in.

Maybe not. There are all those other issues besides the clinical risk-benefit analysis that a drug can get tripped up on. One issue snagged ezogabine; Glaxo and Valeant announced yesterday that the FDA had turned down the drug for now.

Which issue? The duo aren't saying. The abbreviated press release just said that it was for "non-clinical reasons." Glaxo and Valeant plan to respond to the questions "as soon as possible in 2011."

My guess is that REMS is the likely culprit. Ezogabine has some urinary side effects. The FDA likely wants to make sure doctors and patients know the risks and what to look for. The drug also isn't going to be a frontline therapy for epilepsy -- it'll only be used when other drugs aren't working -- so the FDA may want to make sure there's a mechanism in place to ensure doctors are prescribing it correctly.

Fixing a REMS isn't a big deal; Amgen (Nasdaq: AMGN  ) got its taken care of super quick. Even if it's some other issue -- perhaps manufacturing or maybe some preclinical lab work -- that's still better than having to go back into the clinic. Eli Lilly (NYSE: LLY  ) and Amylin Pharmaceuticals (Nasdaq: AMLN  ) got sent back, and it looks like the resulting delay could be more than a year.

It sure would be nice if Glaxo and Valeant had been a little more forthcoming with the reason for the FDA rejection, but investors will just have to accept their word that the drug will be back in front of the FDA soon enough.

Anand Chokkavelu says this "risky" stock isn't that risky.

The Fool owns shares of and has written covered calls on GlaxoSmithKline, which is a Motley Fool Global Gains choice. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 03, 2010, at 7:55 PM, bionick wrote:

    Well,lets see first amln and alks get delayed,now it is vrx and gsk.Also, why the delay for hgsi?But we must remember the FDA loves to play God.I bet there would be no delays if one of them had epilepsy,diabetes,or lupus.Maybe they just need their palms greased a little bit more.Remember,this is the same people that approved vioxx with no delays not to mention avandia and darvocet.Boy oh boy they can be as far off as the local weather person and still get paid.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1387480, ~/Articles/ArticleHandler.aspx, 11/24/2014 12:59:37 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement